Earnings Per Common Share

12 Months Ended

Dec. 31, 2022

Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented.

Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.

Refer to Note 13 for a discussion of the sale of shares under and settlement of forward sales agreements during the periods presented. The Company considered the potential dilution resulting from the forward agreements to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. The aggregate effect on the Company’s diluted weighted-average common shares for the years ended December 31, 2022, 2021, and 2020 was zero, 1 thousand, and 201 thousand weighted-average incremental shares, respectively, from the forward equity sales agreements.

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):


	Year Ended December 31,
	2022		2021		2020
Numerator
Income (loss) from continuing operations	$	513,540	$	137,728	$	160,507
Noncontrolling interests’ share in continuing operations	(15,975)		(17,851)		(14,394)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	497,565		119,877		146,113
Less: Participating securities’ share in continuing operations	(2,657)		(3,269)		(2,416)
Income (loss) from continuing operations applicable to common shares	494,908		116,608		143,697
Income (loss) from discontinued operations	2,884		388,202		267,746
Noncontrolling interests’ share in discontinued operations	—		(2,539)		(296)
Net income (loss) applicable to common shares - basic and diluted	$	497,792	$	502,271	$	411,147




Denominator
Basic weighted average shares outstanding	538,809		538,930		530,555
Dilutive potential common shares - equity awards(1)	338		310		300
Dilutive potential common shares - forward equity agreements(2)	—		1		201

Diluted weighted average common shares	539,147		539,241		531,056
Basic earnings (loss) per common share
Continuing operations	$	0.92	$	0.22	$	0.27
Discontinued operations	0.00		0.71		0.50
Net income (loss) applicable to common shares	$	0.92	$	0.93	$	0.77
Diluted earnings (loss) per common share:
Continuing operations	$	0.92	$	0.22	$	0.27
Discontinued operations	0.00		0.71		0.50
Net income (loss) applicable to common shares	$	0.92	$	0.93	$	0.77

_______________________________________

(1)For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).

(2)For the year ended December 31, 2022, all 9.1 million shares that were settled during the year then ended were anti-dilutive. For the year ended December 31, 2021, all 9.1 million shares that were not settled during the year then ended were anti-dilutive. For the year ended December 31, 2020, represents the dilutive impact of 32 million shares that were settled during the year then ended.

For the years ended December 31, 2022, 2021, and 2020, all 7 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive.